SAN FRANCISCO – “Really great momentum” going into the J.P. Morgan Healthcare Conference this year seems likely to persist, at least through 2014, said Thomson Reuters Recap analyst Laura Vitez. Read More
The biotech initial public offerings (IPO) window is still open. It had been predicted that with the record number of IPOs completed in 2013, investor fatigue might set in this year and these transactions would slow considerably. However, it didn’t take long to prove that this might not be the case. Read More
LONDON – It’s been a busy first week on the job for the new CEO of Santaris Pharma A/S, Donald deBethizy, as a trio of deals was announced, with Roche AG, Glaxosmithkline plc and Isarna Therapeutics GmbH, around the company’s RNA-targeting technology. Read More
Immunomedics Inc. took a major step forward in its late-stage pipeline with the launch of the Phase III registration study of its pancreatic cancer drug, yttrium-90 (90Y)-clivatuzumab tetraxetan. Read More
Executives of Chelsea Therapeutics International Ltd. have their work cut out for them Tuesday, as briefing documents released ahead of the Cardiovascular and Renal Drugs Advisory Committee questioned whether data are sufficient to prove the efficacy of previously rejected neurogenic orthostatic hypotension (NOH) drug Northera (droxidopa). Read More
Scientists have engineered a nanoparticle that attaches to white blood cells in the blood stream and essentially uses them to hunt down circulating tumor cells (CTC). Read More
Immunocellular Therapeutics Ltd., of Los Angeles, issued a letter to shareholders about its ICT-107 program in newly diagnosed glioblastoma (GBM), indicating the company is continuing to analyze data from the trial and consulted with neuro-oncology experts to determine its next development and regulatory activities for ICT-107. Read More
Neurocrine Biosciences Inc., of San Diego, said NBI-98854, a small-molecule VMAT2 inhibitor, in development for tardive dyskinesia, showed an excellent safety profile and a clinically meaningful reduction in tardive dyskinesia symptoms in up to 12 weeks of continuous dosing in a Phase IIb trial. Read More
A team from City of Hope National Medical Center has shown that brain metastases of breast cancer take on brain cell-like properties, which may be what allows them to colonize the brain in the first place. Read More
